Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Adeoye O, Broderick J, Derdeyn C, Grotta J, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne A, Khatri P, Levine S, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo A, Barreto A. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. New England Journal Of Medicine 2024, 391: 810-820. PMID: 39231343, DOI: 10.1056/nejmoa2314779.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsArginineCombined Modality TherapyDrug Therapy, CombinationEptifibatideFemaleFibrinolytic AgentsHumansIncidenceInfusions, IntravenousIntracranial HemorrhagesIschemic StrokeMaleMiddle AgedPeptidesPipecolic AcidsPlatelet Aggregation InhibitorsSingle-Blind MethodSulfonamidesThrombectomyThrombolytic TherapyTreatment OutcomeConceptsSymptomatic intracranial hemorrhageIntravenous argatrobanIntravenous thrombolysisAcute ischemic strokeIntracranial hemorrhageIschemic strokeIncidence of symptomatic intracranial hemorrhageSymptom onsetIschemic stroke treated with intravenous thrombolysisAcute ischemic stroke treated with intravenous thrombolysisStroke treated with intravenous thrombolysisAssociated with increased mortalityRankin Scale scoreInitiation of thrombolysisControlled clinical trialsTreatment of acute ischemic strokePlacebo groupEptifibatide groupEfficacy outcomesArgatroban groupStandard treatmentAdjunctive treatmentPlaceboClinical trialsArgatroban